An observational study in Prostatic Hyperplasia, sponsored by Boehringer Ingelheim. Completed. Open to male participants. Per ClinicalTrials.gov, last updated 2014-09-19.
Sponsored by Boehringer Ingelheim · Observational
Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment after switch from Terazosin-treatment
803 studies on the registry are indexed under Prostatic Hyperplasia; 174 are open to participants now.
This study's enrollment of 4,575 is above the median of 215 across 169 observational studies indexed under Prostatic Hyperplasia.
Browse Prostatic Hyperplasia studies →Boehringer Ingelheim is the lead sponsor of 2,297 studies on the registry; 56 are open to participants now.
Of its 166 completed or terminated interventional studies of FDA-regulated products, 121 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with symptomatic BPS, who switched for ALNA® after preceding Terazosin therapy recruited at urologists
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: ALNA®
Change from baseline in International Prostatic Symptom Score (IPSS) by means on patient questionnaire
Time frame: Baseline, after 1 month
Change of Quality of Life (QoL) Index by means on patient questionnaire
Time frame: Baseline, after 1 month
Global comparative assessment of Terazosin and ALNA® treatment by investigator on a 3 point-scale
Time frame: after 1 month
Change from Baseline in maximum urinary flow rate (Qmax)
Time frame: Baseline, after 1 month
Change from Baseline in residual urinary volume
Time frame: Baseline, after 1 month
Change from Baseline in blood pressure
Time frame: Baseline, after 1 month
Change from Baseline in Pulse rate (bpm)
Time frame: Baseline, after 1 month
Change in complications due to low blood pressure
Patient is asked for complications (weakness, dizziness, nausea)
Time frame: Baseline, after 1 month
Global assessment of efficacy by investigator on 4-point scale
Time frame: after 1 month
Global assessment of tolerability by investigator on 4-point scale
Time frame: after 1 month
Global assessment with BPS- treatment by investigator on a 4-point scale
Switch from Terazosin therapy to ALNA®
Time frame: Baseline, after 1 month
No study locations are listed for this record.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.